Friday , August 19 2022

The Israeli lecture, which helps to cure cancerous diseases, has the FDA's approval


The US Department of Food and Drug Administration (FDA) is a new cancer-based drug to fight specific genetic mutations, not a specific type of cancer.

Vitakvi (generic: larotrectinib) is the first drug to treat disease, initially determined not only by cancer but by genetic mutations.

Bayer and his partner, Loxo Oncologic, are not against tumors in all organisms with certain biomarkers, rather than tumors.

David Hayman, Head of the Medical Development Service, considers rhetorical methods of FDA as an important milestone in the treatment of neuromuscular diseases, which combines the cancer factor with the NTRB gene. Early Memorial was Sloan Kettering Cancer Center and global researcher of clinical trials.

"Despite the age of the patient or the type of cancer, I have seen the first hand in treating TB, which provides clinically important responses to patients with TTS synthesis cancer. Now we have the first allowed therapy for this genomic change, regardless of the type of malignant tumor, "said Heiman.

But it is very expensive: the monthly cost of the oral version is $ 32,800, down about $ 400,000 a year, according to Loxo Oncology at the US Department of Justice report.

Bayer opened two accessible programs: patients will not be receiving clinical benefit within 90 days of the commencement of treatment, and secondly, compensation and patient care services will be paid.

Bayer Paternity Assistance Foundation is also a charitable organization that helps eligible patients receive free medicines from the company.

"Traditionally, in cancer treatment, we treat patients with cancer and part of the body. The distinctive feature of Vitakvi is that he works wherever he or she is, as long as there is no real mutation, "said David Hayman. Memorial Sloan Kettering Cancer Center In New York.

"Today's approval is an important step toward treating cancer, based on genetics of tumors rather than the body's origin," said Scott Gottlieb, FDA commissioner.

"Now we have the right ability to provide the correct treatment of patients in time. "This kind of drug development involving patients with various tumors, which includes genetic mutations, was not possible ten years ago because we did not know much about such oncological mutations."

Source link